Acadia Pharmaceuticals (ACAD) Income towards Parent Company (2010 - 2026)

Acadia Pharmaceuticals has reported Income towards Parent Company for 17 years, with the latest figure at $3.7 million in Q1 2026.

• For the quarter ending Q1 2026, Income towards Parent Company fell 80.53% year-over-year to $3.7 million; the trailing twelve-month figure through Mar 2026 stood at $375.7 million (up 64.12% YoY), and the FY2025 full-year result was $391.0 million, up 72.66% from the prior year.
• Income towards Parent Company for Q1 2026 stood at $3.7 million, down from $273.6 million in the prior quarter.
• The five-year high for Income towards Parent Company was $273.6 million in Q4 2025, with the low at -$113.1 million in Q1 2022.
• Average Income towards Parent Company over 5 years is $20.2 million, with a median of $16.6 million recorded in 2024.
• Year-over-year, Income towards Parent Company slumped 139.74% in 2023 and jumped 2822.13% in 2024.
• Tracing ACAD's Income towards Parent Company over 5 years: stood at -$41.7 million in 2022, then soared by 209.8% to $45.8 million in 2023, then surged by 214.15% to $143.8 million in 2024, then surged by 90.3% to $273.6 million in 2025, then tumbled by 98.65% to $3.7 million in 2026.
• The last three Income towards Parent Company figures came in at $3.7 million (Q1 2026), $273.6 million (Q4 2025), and $71.8 million (Q3 2025), per Business Quant data.

Peer Comparison